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Abstract
Background: In non-obstructive azoospermia, histological patterns of Sertoli cell-only Syndrome (SCO) and
hypospermatogenesis (H) are commonly found. In these pathologies, Leydig cell hyperplasia (LCH) is detected in
some patients. Since TGF-b1 is involved in cellular proliferation/development, the aim of this work was to analyze
the expression of TGF-b1, its receptors TGFBRII, TGFBRI (ALK-1 and ALK-5), and the co-receptor endoglin in human
biopsies from patients with idiopathic infertility.
Methods: Specific immunostaining of TGF-b1, its receptors TGFBRII, TGFBRI (ALK-1 and ALK-5), co-receptor
endoglin and Smads proteins, were carried out in testicular biopsies from normal and infertile men with SCO or H.
Gene expression of TGF-b1 system were made in biopsies from infertile patients with semi-quantitative and
quantitative PCR.
Results: Immunohistochemical studies revealed that TGF-b1 and its specific receptors are present in Leydig cells in
biopsies from normal tissue or patients with SCO or H with or without LCH. Smad proteins, which are involved in
TGF-b1 signaling, are also detected in both their phosphorylated (activated) and dephosphorylated form in all
samples TGF-b1, ALK-1 and endoglin gene expression are stronger in human biopsies with LCH than in those with
SCO or H. Neither TGFBRII nor ALK-5 gene expression showed significant differences between pathologies. A
significant correlation between ALK-1 and endoglin expression was observed.
Conclusions: In conclusion, the high levels of mRNA and protein expression of the TGF-b1 system in patients with
LCH, particularly ALK1 and its correlation with endoglin, suggest that these proteins acting in concert might be, at
least in part, committed actors in the Leydig cell hyperplasia.
Background
Primary testicular failure affects approximately 1% of all
men and 10% of those who seek fertility evaluation. The
most common histological patterns found in testicular
biopsies of azoospermic men (non-obstructive azoosper-
mia) are either Sertoli cell-only Syndrome (SCO) or
hypospermatogenesis (H) [1]. It has been reported that
in some of these patients, Leydig cells show hyperplasia
(LCH). Two different types of LCH have been described:
nodular and diffuse LCH [2]. Identification and charac-
terization of the factors involved in this alteration might
be a clue on the understanding of the source of this
pathology and could bring new insights into the thera-
peutic approach.
In experimental animals, LCH may be induced by a
number of hormones, enzymes and chemicals [3]. In
this context, some reports have indicated that LH,
androgens and/or even estrogens might stimulate the
division of Leydig cells [4,5]. Leydig cell function is pre-
dominantly controlled by gonadotropins. However, a
number of intratesticular factors are known to influence
Leydig cell steroidogenic function [6]. Among these fac-
tors, TGF-b1 modulates Leydig cell steroidogenesis [7]
and proliferation [8,9]. In this context, Sanderson et al.
[10] have demonstrated that, in transgenic mice overex-
pressing TGF-b1, Leydig cells are prominent.
In several tissues, the TGF-b family has a critical role in
the regulation of cell cycle progression and differentiation,
in both normal and pathological conditions [11-13].
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cesses, including the secretory function of Leydig and
Sertoli cells, as well as the organization of peritubular
myoid cells, testis development and spermatogenesis
[13-15]. In addition, the absence or overexpression of
this factor affects male reproductive function, supporting
the hypothesis that TGF-b signaling pathways are care-
fully coordinated during testicular development and
spermatogenesis [13,16,17].
TGF-b1 exerts its effects via specific type I and II ser-
ine/threonine kinase receptors. Type II receptor
(TGFBRII) transphosphorylates and activates type I
receptor (TGFBRI), which then phosphorylates and acti-
vates its downstream nuclear effectors, named Smads
[ 1 2 ] .I th a sb e e nd e s c r i b e dt h a tT G F - b1 activates two
distinct type I receptors: activin receptor-like kinase-1
(ALK-1), which promotes Smad 1/5 phosphorylation,
and ALK-5, which induces Smad 2/Smad 3 phosphoryla-
tion [18]. Activation of ALK-1 stimulates cell prolifera-
tion and migration, whereas activation of ALK-5 inhibits
these responses. Endoglin, a TGF-b1c o - r e c e p t o r ,i s
thought to modulate TGF-b1 responses leading to cell
proliferation [19]. In endothelial cells, endoglin blocks
TGF-b1 induced growth arrest by promoting ALK-1 sig-
naling, and indirectly reduces ALK-5 signaling [20].
Although the presence of TGF-b1, TGFBRII and
TGFBRI has been described in human testis [21,22], to
our knowledge, there are no reports on the differential
expression of the TGFBRI subtype or its co-receptor.
Thus, the aim of the present study was to analyze
mRNA and protein expression of TGF-b1, its specific
receptors TGFBRII, ALK1 and ALK5, and co-receptor
endoglin, in patients with SCO and H and LCH, and to
study the presence of Smads 2/3 and 1/5 in these
pathologies.
Methods
Patients and testicular samples
The study was designed in accordance with the Helsinki
Declaration and its last modification in Tokyo 2004 on
human experimentation and was approved by The Ethi-
cal Committee of the Durand Hospital (Buenos Aires,
Argentina) and Ethical Committee of the Instituto de
Biología y Medicina Experimental (Buenos Aires, Argen-
tina). Informed Consent was obtained from all the
patients enrolled in the study.
Nineteen men (27-42 years-old) presenting idiopathic
infertility and non-obstructive azoospermia without
infection process were enrolled in this study and were
assessed and diagnosed by open testicular biopsy.
Patients with known etiology of infertility, such as geni-
tourinary infections, mumps orchitis, varicocele, hypogo-
nadotropic hypogonadism, chromosome anomalies,
obstruction or agenesia of seminal ducts were excluded.
The diagnosis of azoospermia was based on the analy-
sis of at least two semen samples collected at different
times and two replicates of each sample were centri-
fuged at 3000 × g for 15 min. All the patients underwent
a detailed physical examination, endocrinology profile
testing and a testicular biopsy. All of them presented
normal cariotype. Non-obstructive azoospermia was
defined by the presence of spermatogenic defects in the
testicular biopsy without evidence of obstruction of the
seminal ducts.
All the patients underwent diagnostic testicular biopsy
or sperm retrieval and agreed to provide a small piece of
testicular tissue (5 mm in diameter) for further studies.
One-third of the tissue volume was immersed in Bouin’s
solution and subjected to histopathological diagnosis.
The testicular histopathology was categorized according
to the most advanced presence of spermatogenesis. Two
pathologists evaluated all testicular slices. Biopsies were
classified either as H or SCO appearance, according to
McLachlan et al. [23]. The H group included men in
which the biopsy specimens contained less than 17
mature spermatids per tubule [24,25]. In addition the
presence or absence of LCH in H and SCO sections was
recorded. In the LCH group, there were more than 7 Ley-
dig clusters of more than 15 cells per 3.14 mm
2,i nf o u r
fields of vision with a 20 × objective [26].
As a consequence, biopsies were classified as SCO
(n = 6), SCO + LCH (n = 2), H (n = 8) and H+LCH
(n = 3) according to testicular morphology.
Two-thirds of the volume of pathological samples was
cryopreserved in liquid nitrogen for molecular biology
studies.
Since ethical and legal considerations hampered the
possibility to obtain testicular samples from healthy
men, histochemistry and studies of molecular biology in
normal tissue were carried out from retrospective sam-
ples kept in paraffin blocks from patients undergoing
bilateral orchiectomy for the treatment of prostate carci-
noma (Normal Group (N), n = 4; 50-60 years old).
Biopsy specimens from N presented a normal number
of mature spermatids per tubule, i.e. more than 17 cells
per tubular cross sections [24,25].
Hormone levels
Before biopsies, a blood sample was taken from patients.
Serum concentrations of FSH (normal range 1.5-7 mIU/
ml), LH (normal range: 1.1-9 mIU/ml) and testosterone
(normal range: 10-30 pmol/ml) were measured by Che-
miluminescence’s assays (Elecsys 1010, Roche).T h e
intra-and interassay coefficient of variation were 2.1%
and 7.5% for FSH, 2.5% and 9.5% for LH, and 5.1% and
8.2% for testosterone respectively. The detection limits
were 0.06 and 0.05 mIU/ml for FSH and LH, and 0.35
pmol/ml for testosterone.
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Bouin’s fixed human testicular specimens were dehy-
drated, embedded in paraffin and sectioned at 5 μm.
Hematoxylin/eosin stain was used to analyze testicular
morphology.
The sections were deparaffinized with 100% xylene
and sequentially rehydrated with 96, 90, 80 and 70%
ethanol. The slides were then blocked with 3% hydrogen
peroxide in absolute methanol for 5 min, washed twice
with phosphate-buffered saline (PBS, pH 7.4) for 5 min
each time. The sections were subjected to saponine
(0.5%) and proteinase K (20 μg/ml) treatments. Nonspe-
cific binding was blocked with normal serum blocking
buffer for 20 min at room temperature. The slides were
incubated over night with the primary antibody (from
Santa Cruz: anti-TGF-b1, sc-146 (1:100); anti TGFb RI
(V-22), sc-402, (1:100); anti TGFb RI (T-19), sc-398
(1:100); p-Smad 2/3, sc 11769 (1:50); Smad 1/5 sc-6031-
R (1:100); endoglin (MJ7/18) sc-18893 (1:50); from Cell
Signaling: Smads 2/3 # 3102 (1:100); p-Smad 1/5 #9511
(1:100). 3b-Hydroxy-steroid dehydrogenase (3b-HSD)
antibody (1/2000) was kindly provided by Dr. J. Ian
Mason (Edinburgh University, United Kingdom).
After five rinses in PBS, sections were incubated for 1
h at room temperature with a biotinylated secondary
antibody (Vector Labs, 1:1000). After further washing in
PBS, sections were incubated for 1 h with the streptavi-
din-peroxidase complex diluted 1:100 (ABC kit, Vector
Labs). The sections were washed twice with PBS and
development of peroxidase activity was performed with
0.055% w/v 3,3’-diaminobenzidine and 0.1% v/v H2O2 in
Tris-HCl. Sections were then washed with distilled
water. Negative controls were processed simultaneously
by omitting the primary antibodies and were treated
with preimmune serum.
The intensity of TGF-b1 and ALK-1 immunostaining
was evaluated with the Software Nikon NIS-Elements
Basic Research, version 3.0
RNA isolation and semiquantitative RT-PCR for the normal
group
Consecutive sections (slices of 5 μm) of paraffin blocks
(n = 6 slices from each block) were scratched from the
slides, deparaffinized and treated with Trizol (Invitro-
gen) to obtain total RNA. Total RNA was used for a
DNAase treatment (Invitrogen) followed by a reverse
transcription reaction in the presence of MMLV reverse
transcriptase (Promega, 200 U/ul) and random hexamer
primers (Biodynamics). cDNAs (10 μl) were used to
amplify mRNA sequences by a PCR reaction with
Go-TaqDNA polymerase (Promega, 5U/ul) and specific
primers (1 uM)(Table 1). The first denaturation was
performed at 94 °C for 4 min. The successive denatura-
tion steps were performed at 94 °C for 1 min followed
by annealing at specific temperature for 1 min and
extension at 72 °C for 90 sec. Forty-five cycles were
used for each pair of primers. A final elongation of 7
min at 72 °C was used to amplify the transcripts. The
amplified cDNA fragments were size-fractioned in 2%
agarose gel and visualized in ethidium bromide.The den-
sity of bands was quantified with the Scion Image soft-
ware (NIH).
RNA isolation, semiquantitative and quantitative RT-PCR
for infertile patients
Total RNA from human biopsies was extracted with
Trizol (Invitrogen) according to the manufacturer’s
instructions. Total RNA (0.4 ug) was treated with DNA-
seI (Invitrogen) and used for reverse transcription reac-
tion in a 20 μl reaction using M-MLV reverse
transcriptase (Promega, 200 U/ul) and random hexamers
primers (Biodynamics).
Reverse-transcribed cDNAs (5 μl) were used to
amplify mRNA sequences by a semiquantitative PCR
reaction with Go-TaqDNA polymerase (Promega, 5U/
ul) and specific primers (1 uM) (Table 1). The first
denaturation was performed for 4 min at 94 °C. The
successive denaturation steps were performed at 94 °C
for 1 min, followed by annealing at specific tempera-
ture for 1 min and extension at 72 °C for 90 sec.
Thirty cycles were used for each pair of primers. A
final elongation of 7 min at 72 °C was used to amplify
transcripts. The housekeeping gene used was b-Actin
(25 cycles). The amplified cDNA fragments were size-
fractionated in 2% agarose gel and visualized by stain-
ing with ethidium bromide. The intensity of bands
obtained by electrophoresis was evaluated by Scion
Image for Windows software. Results are expressed as
the ratio between the expression of the specific gene
and b-actin.
For quantitative real-time PCR, cDNA was amplified
in an ABI PRISM 7700 Sequence Detection System
(Applied Biosystems), using SYBR Green Master Mix
Reagent (Applied Biosystems). The forward (F) and
reverse (R) primers used were: TGF-b1: F: CCCAG-
CATCTGCAAAGCTC; R: GTCAATGTACAGCTG
CCGCA; ALK-1: F: TCTCAGGCCTAGCTCAGATGAT;
R: TAGGCTTCTCTGGACTGTT G C T ;e n d o g l i n :F :
CATCCTTGAAGTCCATGTCCTCTT, R: GCCAGG
TGCCATTTTGCTT; GADPH: F: TGCACCACCAAC
TGCTTAGC; R: GGCATGGACTGTGGTCATGAG.
Each primer was used at a concentration of 0.3 μMi n
each reaction. Cycling conditions were as follows:
step 1, 10 min at 95 °C; step 2, 15 sec at 95 °C; step 3,
30 sec at 55 °C; step 4, 30 sec at 60 °C, repeating from
step 2 to step 4 40 times. Data from the reaction
were collected and analyzed by the complementary com-
puter software (Sequence Detection Software, Applied
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confirm specificity of the signal. Relative quantification
of gene expression was calculated using standard curves
and normalized to GADPH in each sample. In order to
confirm the best housekeeping gene we evaluated gene
expression of GADPH, 18 s and actin. GADPH showed
a lesser CV (3%) than other genes (18s:8 . 6 %a n dactin:
9.3%).
For the assessment of quantitative differences in the
cDNA target between samples, the mathematical model
of Pfaffl [27] was applied. An expression ratio was deter-
mined for each sample by calculating (Etarget)
ΔCt(target)/
(EGAPDH)
ΔCt(GAPDH), where E is the efficiency of the pri-
mer set and ΔCt = Ct (normalization cDNA) -C t(experimental
cDNA). The amplification efficiency of each primer set
was calculated from the slope of a standard amplifica-
tion curve of log (ng cDNA) per reaction vs. Ct value
(E = 10
-(1/slope)). Efficiencies of 2 ± 0.1 were considered
optimal.
Statistical analysis
Statistical analysis was performed using Graph Pad
Prism (version 3.00 for Windows GraphPad software,
San Diego California, USA) for one-way analysis of var-
iance. Data are expressed as mean ± SEM. Tukey’sM u l -
tiple Comparison or Newman-Keuls tests were used
when differences between more than two groups were
compared. A p-value of less than 0.05 was considered
significant. Pearson’s correlation coefficient was also cal-
culated between variants.
Results
Hormonal serum levels
Serum levels of testosterone, LH and FSH are shown in
Table 2. Testosterone serum levels were within the nor-
mal range in the whole population. FSH levels were
above the normal range in 12/19. FSH serum concentra-
tion in SCO and LCH groups were increased respect to
N or H group. LH serum levels were above normal
range in 3/19 patients and there were no significant dif-
ferences between groups.
Immunohistochemistry of TGF-b1, ALK 1 and 5 and Smad
proteins in normal testicular tissue
The immunostaining of TGF-b1 was clearly detected in
Leydig cells of normal tissue (Figure 1 Panel A). A weak
staining was observed for ALK-5, while a strong staining
was observed for ALK-1 in Leydig cells (Figure 1 Panels
B and C, respectively).
Smads 2/3 (Figure 1 Panel D) were detected in the
cytoplasm of Leydig cells but their phosphorylated
forms (Figure 1 Panel E) were located in the nucleus of
Leydig cells. In the seminiferous tubules (ST), total
Smad 2/3 (Figure 1 Panel D) was observed in the
nucleus of germinal line, whereas p-Smad 2/3 was not
detected (Figure 1 Panel E).
Leydig cells showed a significant staining for Smad 1/5
in the cytoplasm but a weak nuclear staining for p-Smad
1/5 (Figure 1 Panels F and G, respectively). In the ST,
Smads 1/5 (Figure 1 Panel F) were observed in the cyto-
plasm and nucleus of spermatids, spermatogonia and
spermatocytes, whereas their phosphorylated form (Fig-
ure 1 Panel G) was clearly detected in the nucleus of
those cells (Figure 1 Panel F).
Table 1 Oligonucleotide primers used for PCR amplification of cDNAs obtained after reverse transcription from human
testis
Target (Accession number) Sequence of primer (5’___ 3’) Tm (°C) Amplified product (bp)
TGF-b1 (NM_011577) F: TCCTGCTTCTCATGGCCA
R: CCTCAGCTGCACTTGTAG
55 405
TGFBRII (NM_009371) F: GCGCCAACAACATCAACC
R: GGTACTCCTGCAGGTTGC
56 300
ALK-5 (NM_004612) F: GACATCCCTGGTCCATCC
R: TCTGGCACAACTCCACTG
55 299
ALK-1 (NM_000020) F: GTCCTGGTTCCGGGAGA
R: TTGCTCTTGACCAGCACA
55 294
Endoglin (NM_000118) F: GCATCCTTCGTGGAGCTA
R: GACACCTGCATGCCACA
55 300
b- Actin (AJ312092) F: GGATGCAGAAGGAGATCA
R: CTAGAAGCATTTGCGGTG
55 193
F: forward; R: reverse
Table 2 Hormonal serum levels
Pathology FSH (mIU/ml) LH (mIU/ml) T (pmol/ml)
SCO (n = 6) 16.1 ± 1.8
a,b 7.8 ± 1.5 14.5 ± 2.1
H (n = 8) 5.3 ± 0.6
a 4.3 ± 0.3 18.4 ± 1.7
LCH (n = 5) 26.8 ± 6.7
b 7.1 ± 1.7 17.0 ± 2.4
N (n = 4) 3.8 ± 1.1
a 5.2 ± 0.3 21.2 ± 1.7
SCO: Sertoli cell-only Syndrome; H: Hypospermatogenesis; LCH: Leydig Cell
Hyperplasia. N: normal. Values represent the mean ± SEM. Tukey’s Multiple
Comparison was done between groups. Different letters indicate significant
differences between groups (p < 0.005).
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endoglin in testicular pathologies
Specific immunohistochemical analysis revealed the pre-
sence of TGF-b1 in the cytoplasm of testicular Leydig
cells of all patients (Figure 2). The intensity of TGF-b1
immunostaining in patients with LCH was higher than
that in patients without LCH (SCO vs SCO+LCH: 2.7
fold, p < 0.01; H vs H+LCH: 3.8 fold, p < 0.05).
ALK-5 immunostaining (Figure 2) was weak in Leydig
cells in pathological biopsies, but strong in ST of SCO
patients. Co-localization of ALK-1 and 3b-HSD, a mar-
ker of Leydig cells, was evaluated in consecutive sections
by immunohistochemistry. ALK-1 immunostaining (Fig-
ure 2) was stronger in Leydig cells of LCH patients than
in patients without LCH (SCO vs SCO+LCH: 2.1 fold, p
< 0.01; H vs H+LCH: 1.7 fold, p < 0.05).
Endoglin was present in SCO or H with LCH group
but not detected in normal tissue (Figure 3).
Immunohistochemistry of Smad proteins in human
pathologies
Total Smads 2/3 and their activated phosphorylated
forms were detected in SCO, H and LCH patients.
These proteins were observed mainly in SCO patients
that presented LCH (Figure 4).
Patients of the H group presented Smad 1/5 staining
in the cytoplasm of Leydig cells and in the nucleus of
spermatids and spermatogonias. However, p-Smad 1/5
signaling was detected in the cytoplasm and nucleus of
Leydig cells and in the nucleus of all cells of the germ
line.
Patients of the SCO group showed a clear staining of
Smad 1/5 in the cytoplasm of Leydig cells that was
more evident in SCO patients with LCH. The activated
form, p-Smad 1/5, was observed in the nucleus of Ley-
dig cells as well as in some Sertoli cells.
TGF-b1, TGFBRII, ALK-1, ALK-5, and endoglin expression in
normal tissue
The expression of TGF-b1, TGFBRII, ALK-1, ALK-5 and
endoglin in normal testicular tissue is shown in Figure 5.
A clear band for the expected molecular weight was
observed for each cDNA analyzed, revealing the pre-
sence of these components of the TGF-b1s y s t e mi n
normal tissue.
TGF-b1, TGFBRII, ALK-1 ALK-5 and endoglin expression in
pathological tissue
Semiquantitative PCR of the TGF-b1s y s t e ms h o w e d
that neither TGFBRII nor ALK-5 exhibited significant
differences between the experimental groups, but the
mRNA expression of TGF-b1, ALK-1 and endoglin were
significantly increased in patients with LCH respected to
the other groups (data not shown). Since the prolifera-
tive action of TGF-b1 depends only of ALK-1 and endo-
glin, and not of TGFBRII and ALK-5,w ef u r t h e r
performed a quantitative PCR to confirm these results.
TGF-b1, ALK-1 and endoglin mRNA clearly showed a
significant increase in testicular biopsies from LCH
group (independently of whether LCH derived from
S C Oo rH )t h a ni nS C Oo rH( F i g u r e6P a n e l sA ,B
and C) (p< 0. 05).
Statistical analysis showed a positive correlation
between ALK-1 and endoglin expression (r = 0.4915
Pearson; p < 0.05) (Figure 6 Panel D) independently of
the pathology.
Figure 1 TGF-b1 system in normal testes. Sections of normal testes showing immunohistochemistry of TGF-b 1( P a n e lA ) ;A L K - 5( P a n e lB ) ;
ALK-1 (Panel C), Smad 2/3 (Panel D), p-Smad 2/3 (Panel E); Smad 1/5 (Panel F); p-Smad 1/5 (Panel G). Magnification 400×.
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Testicular LCH is a benign condition in which the
hyperplasic cells infiltrate between ST [28]. Adult
patients with LCH are usually infertile. No cause can
account for all cases of LCH. In this context, the study
of some factors involved in the proliferation of Leydig
cells might contribute to the understanding of this
pathology. Some reports [28] have suggested that an
increase in serum LH can result in LCH. However, in
the present study, the serum LH levels of patients
were within the normal range. Clegg et al. [3] pro-
posed that an alteration of the production of paracrine
growth factors could result in growth stimulation
without major effects on the circulating LH levels. FSH
levels are increased in SCO and LCH patients. These
results are in agreement with those of other authors
[1,29], who have described that the increased FSH
levels in SCO patients are due to the lack of inhibin, a
main regulator of FSH secretion by a negative feedback
mechanism.
T h ep r e s e n c eo fT G F - b1, TGFBRII and TGFBRI has
long been described in human testis [21,22]. In the pre-
sent work, we analyzed the TGF-b1 system in SCO and
H with or without LCH. The histochemistry of TGF-b1
showed the presence of this peptide in the cytoplasm of
Leydig cells from patients with SCO, H and LCH. The
Figure 2 Localization of TGF-b1, ALK-5 and ALK-1 in testicular pathologies. Panel A: Immunostaining of TGF-b1a n dA L K - 5i nt e s t i c u l a r
pathologies. Panel B: Immunostaining in serial sections of ALK-1 and 3b-hydroxysteroid dehydrogenase (3b-HSD) in testicular pathologies.
H: Hypospermatogenesis, SCO: Sertoli cell-only Syndrome, LCH: Leydig Cell Hyperplasia, ST: Seminiferous Tubules, LC: Leydig cell. Magnification
400 x.
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that present LCH than in patients with normal Leydig
cell morphology.
Dobashi et al.[21] demonstrated by immunohisto-
chemistry that the presence of extracellular and intracel-
lular TGF-b1 is higher in SCO patients than in normal
controls and determined that the serum level of this
cytokine is higher in this group of patients. In the pre-
sent study, we also detected an increase in TGF-b1
immunostaining in H patients with LCH. In addition,
mRNA molecular analyses showed that gene expression
of TGF-b1 resembles that observed by immunohisto-
chemistry studies; i.e., the mRNA of this cytokine is
higher in LCH than in SCO or H patients.
Several authors have detected TGBRI, however, no
information about differential expression of ALK-1 and
5 in human testicular tissues are published. Zhang et
al. [22] have demonstrated, in normal men, that the
staining for TGFBRI protein is stronger in the testicu-
lar interstitium, i.e. Leydig cells, weaker in the Sertoli
cells, and not detectable in spermatogonia and primary
spermatocytes. According tot h er e s u l t so b t a i n e dw i t h
antibody used by these authors, the ALK-5 receptor
was the subtype detected. In our study, ALK-5 gene
expression did not show significant differences
between groups. Konrad et al. [30] have described that
TGF-b1 exerts an apoptotic effect. Thus, we could
speculate that the absence of germinal cells is a
consequence of the action of TGF-b1, via ALK-5
receptor, on seminiferous tubules.
In the present study, we observed that ALK-5 is
immunohistochemically localized in Leydig cells and
show a weak staining in ST of normal men. However,
SCO patients showed a strong staining in this testicular
compartment. On the other hand, ALK-1 staining is
sparsely present in normal Leydig cells but stronger in
LCH. ALK-1 gene expression is also higher in testes
from LCH than in those from SCO or H. To our knowl-
edge, this is the first report showing the cellular localiza-
tion of ALK-1 in normal and pathological testes.
Suszko and Woodruff [31] have pointed out that the
availability and activity of the receptor can influence a
particular signaling pathway. These authors considered
that the receptor activity and the length of their active
state are also crucial to facilitate a particular cellular
response. In this context, it is important to remark that
the TGFBRI receptor has been associated with choles-
terol-rich membrane microdomains, known as caveolae,
and consequently, with the suppression of TGF-b1-
mediated phosphorylation of Smad2 [32,33].
Immunohistochemistry showed a clear staining of
endoglin in Leydig cells of the LCH group but not in
those of normal tissue. On the other hand, we detected
the expression of endoglin mRNA in normal and patho-
logical tissues, and found that it was higher in LCH
patients than in other groups.
Figure 3 Immunolocalization of endoglin. N: normal, H: Hypospermatogenesis, SCO: Sertoli cell-only Syndrome, LCH: Leydig Cell Hyperplasia,
ST: Seminiferous Tubules, LC: Leydig cell. Magnification 400 x.
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different sensitivities of the two methods (PCR and his-
tochemistry). Besides, it is possible that the mechanism
of endoglin mRNA transduction into protein in normal
tissue was diminished. Different mechanisms of post-
transcriptional control have been described: elongation
and termination, alternative RNA splicing, 3’cleavage
and polyadenylation, nuclear export, regulation of stabi-
lity and translation of mRNAs and regulation of the
subcellular location of specific mRNAs.
Statistical studies revealed a correlation between ALK-
1 and endoglin gene expression. Since in endothelial
cells ALK-1 and endoglin have been involved in TGF-b1
signaling leading to proliferation [20], we could specu-
late that these components of the TGF-b1 system might
participate in the proliferation of Leydig cells observed
in LCH patients.
Several studies have suggested that Smad proteins are
the intracellular mediators of TGF-b signaling [34-36].
These transcription factors translocate to the nucleus
upon ligand stimulation. There is scarce information
about Smad proteins in human testes since the limita-
tion of tissue access precludes knowledge of the charac-
terization of TGF-b1 signaling components. Thus, we
aimed to analyze the presence of these proteins in testi-
cular biopsies from our patients. We observed that total
Smad 2/3 and 1/5 are present in Leydig cells, mainly in
the LCH group. Moreover, both phosphorylated iso-
forms were detected.
Sun et al. [37] observed an increase in Smad2 expres-
sion in SCO syndrome compared to normal men, but
did not report the presence or absence of LCH. Narula
et al. [16] have described LCH, apoptosis of germ cells
and spermatogenic arrest in transgenic mice overexpres-
sing the common factor Smad4.
In the mouse postnatal testis, mRNA and protein
Smad1 have been detected in spermatocytes and round
spermatids [38]. Smad 5 protein has been reported only
Figure 4 Immunolocalization of Smad 2/3, p-Smad 2/3, Smad 1/5 and p-Smad 1/5 in human pathologies. ST: Seminiferous Tubules, LC:
Leydig cell. Magnification 400 x
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Page 8 of 11in prepubertal mouse testes, being restricted to sperma-
togonia [39]. Reports of Smad 4 show a ubiquitous loca-
lization in mouse testes [39,40], whereas it seems to
have a specific Leydig cell localization in the rat [40].
Recently, we have described the hormonal regulation
of TGF-b1 system in an experimental model [41] and
that the in vitro effect of TGF-b1 on mouse Leydig cell
induces Smad 1/5 phosphorylation and proliferation
markers (Bax/Bcl-2 ratio, PCNA) [41].
Expression of different receptor subtypes would allow
to Leydig cells to mount an appropriate response to
extracellular stimulation by the differential presence and
phosphorylation of Smad proteins, leading to activation
of distinct target genes.
Whether the high expression of the TGF-b1s y s t e m
observed in patients with LCH is a cause or a conse-
quence of this pathology should be analyzed. Unfortu-
nately, physiological studies can not be developed in
testicular biopsies. Thus, further studies using suitable
animal experimental models should be performed in
order to investigate the role of the TGF-b1s y s t e mi n
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Page 9 of 11Leydig cells. In this context, we analyzed that the in vivo
intratesticular administration of this cytokine stimulates
Leydig cell hyperplasia/hypertrophy [42].
Conclusions
Together, the present study and our previous ones
[ 4 1 , 4 2 ]s e e mt oi n d i c a t et h a tt h eL C Ho b s e r v e di n
human biopsies are likely to be, at least in part, due to
the increase in the TGF-b1 system. These studies might
be of great importance to apply this knowledge to key
outcomes in male reproductive health.
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